Cited by 25Treatment of Major DepressionElectroconvulsive Therapy StudiesSuicide and Self-Harm Studies

Ketamine vs midazolam: Mood improvement reduces suicidal ideation in depression

Open access
Hochschild, Annabella, Keilp, John G., Madden, Sean P., Burke, Ainsley K., Mann, J. John, Grunebaum, Michael F.·2022·Journal of Affective Disorders

Abstract

Objective Studies demonstrate rapid antidepressant and anti-suicidal ideation effects of subanesthetic ketamine. The specific subcomponents of depression that are most closely tied to reduction of suicidal ideation with ketamine treatment are less explored.Methods Exploratory, post hoc analysis of data from a randomized clinical trial of ketamine vs midazolam in patients with major depressive disorder (MDD) and clinically significant suicidal ideation examined changes in factor analysis-derived symptom clusters from standard measures of depression (Hamilton Depression Rating Scale, HDRS; Beck Depression Inventory, BDI) and mood disturbance (Profile of Mood States, POMS), and their relationship to severity of suicidal ideation (Beck Scale for Suicidal Ideation; SSI). Ratings obtained before and one day after blinded intravenous infusion were decomposed into component factors or published subscales. Treatment effects on factors/subscales were compared between drugs, correlations with changes in suicidal ideation were tested, and stepwise regression was used to derive predictors of change in SSI.Results Factor scores for HDRS Psychic Depression, HDRS Anxiety, BDI Subjective Depression, POMS Depression and POMS Fatigue improved more with ketamine than midazolam. Stepwise regression showed across both drugs that improvement in HDRS Psychic Depression, POMS Depression, and HDRS Anxiety predicted 51.6% of the variance in reduction of suicidal ideation.Limitations Secondary analysis of clinical trial data.Conclusions Ketamine's rapid effects on suicidal ideation appear to be mostly a function of its effects on core mood and anxiety symptoms of MDD, with comparatively little contribution from neurovegetative symptoms with the potential exception of vigor/fatigue.Trial registration Data used in this secondary analysis came from ClinicalTrials.gov identifier: NCT01700829.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jad.2021.12.055

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In a clinical experiment, the reduction in thoughts of suicide among MDD patients receiving ketamine was mostly sustained.

    “In a clinical experiment, the effect of supplementary injection of subanesthetic doses of ketamine on thoughts of suicide in MDD patients was evaluated, and the results showed that the reduction in thoughts of suicide among MDD patients receiving ketamine was mostly sustained. 481”

    From Major depressive disorder: hypothesis, mechanism, prevention and treatment (2024) · cites this paper as [481]

    The Methods (Participants; page unavailable) describe a trial of adjunctive subanesthetic intravenous ketamine in patients with MDD and suicidal ideation. The Discussion reports a greater reduction in suicidal ideation than with midazolam one day after treatment, but this analysis does not establish that the reduction in suicidal thoughts was mostly sustained; its reference to a roughly one-week duration of effect is not specific to that outcome. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 2

  1. First MB, 1997. User's guide for the structured clinical interview for DSM-IV axis II personality disorders: SCID-II. American Psychiatric Press, Washington, DC.
  2. Schatzberg AF, DeBattista C, 2015. Manual of clinical psychopharmacology, Eighth edition. ed. American Psychiatric Publishing, a division of American Psychiatric Association, Washington, DC.

Cited by

Sorted by citations

Authors
Hochschild, A., Keilp, J. G., Madden, S. P., Burke, A. K., Mann, J. J., & Grunebaum, M. F.
Affiliations
Columbia University Irving Medical Center (US)
Corresponding author
Grunebaum, Michael F.
Venue
Journal of Affective Disorders
Publisher
Elsevier BV
Published
2022-03
Volume
300
Pages
10-16
ISSN
0165-0327 (ISSN-L)
OpenAlex
W4200454875
Cited by
25
References
61
Citations by year
2026: 7 · 2025: 8 · 2024: 4 · 2023: 4 · 2022: 2
FWCI
1.46
Type
journal article
Language
en
Open access
Locations
  • Journal of Affective Disorders (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Institute of Mental Health (R01 MH-096,784)
Topics
  • Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
  • Social Sciences › Psychology › Clinical Psychology › Suicide and Self-Harm Studies
Keywords
ketamine, midazolam, suicidal ideation, major depressive disorder, mood improvement, anxiety symptoms, rapid antidepressant effects
MeSH terms
Depression, Major Depressive Disorder, Humans, Ketamine, Midazolam, Suicidal Ideation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review